SK-CO-1细胞

SK-CO-1细胞SK-CO-1细胞系SK-CO-1人结直肠腺癌细胞 

Cell line name SK-CO-1

Synonyms SKCO-1; SKCO 1; SKCO1; SKCol1; SK-Col-1; SK Col 1

Accession CVCL_0626

Resource Identification Initiative To cite this cell line use: SK-CO-1 (RRID:CVCL_0626)

Comments Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: NCI RAS program mutant KRAS cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-072.

Population: Caucasian.

Doubling time: 46.56 hours (PubMed=25944804); 46 hours (PubMed=25984343).

Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053; Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

Sequence variations

Mutation; HGNC; HGNC:583; APC; Simple; p.Phe1089fs*37 (c.3266delT); Zygosity=Heterozygous (ATCC=HTB-39; Cosmic-CLP=909718; DepMap=ACH-000400).

Mutation; HGNC; HGNC:583; APC; Simple; p.Pro1443fs*30 (c.4328delC); Zygosity=Heterozygous (ATCC=HTB-39; Cosmic-CLP=909718; DepMap=ACH-000400).

Mutation; HGNC; HGNC:4392; GNAS; Simple; p.Arg201Cys (c.601C>T); ClinVar=VCV000015933; Zygosity=Heterozygous (Cosmic-CLP=909718; DepMap=ACH-000400).

Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; Cosmic-CLP=909718; DepMap=ACH-000400).

Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*01:01,02:01

HLA-B B*35:08,58:05

HLA-C C*05:01,07:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0.04

Native American 0.56

East Asian, North 2.24

East Asian, South 0

South Asian 0

European, North 68.7

European, South 28.45

Disease Colon adenocarcinoma (NCIt: C4349)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Male

Age at sampling 65Y

Category Cancer cell line

STR profile Source(s): ATCC=HTB-39; Cosmic-CLP=909718; PubMed=25877200; PubMed=25926053; Technion Genomics Center

 

Markers:

Amelogenin X (PubMed=25877200)

X,Y (ATCC=HTB-39; Cosmic-CLP=909718; PubMed=25926053; Technion Genomics Center)

CSF1PO 13

D1S1656 13,18.3

D2S441 10,15

D2S1338 17,21

D3S1358 17,18

D5S818 9,11

D7S820 8,10

D8S1179 12,14

D10S1248 13,14

D12S391 18

D13S317 14

D16S539 13

D18S51 19

D19S433 12,13

D21S11 28,30

D22S1045 15

FGA 20,25

Penta D 11

Penta E 13,16

TH01 8,9

TPOX 8,11

vWA 18,19

 

Run an STR similarity search on this cell line

Web pages

Publications

DOI=10.1007/978-1-4757-1647-4_5

Fogh J., Trempe G.L.

New human tumor cell lines.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York; USA (1975)

 

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

 

PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

 

PubMed=6220172

Dracopoli N.C., Fogh J.

Polymorphic enzyme analysis of cultured human tumor cell lines.

J. Natl. Cancer Inst. 70:469-476(1983)

 

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

 

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

 

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)